Orphazyme
1,020 DKK -7.02%Be the first to follow this company
Orphazyme operates in biochemistry. The company specializes in research and development of unusual diseases where there is a deficiency in the function of heat coke proteins. The technique is based on arimoclomol, which stimulates the production of heat coke proteins in cells that experience increased degrees of stress and toxicity. Diseases that the company's products aim to treat include Gaucher's disease and amyotrophic lateral sclerosis (ALS). The company is headquartered in Copenhagen.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Copenhagen
ORPHA
Daily low / high price
989.6 / 1,096
DKK
Market cap
36.02M DKK
Turnover
11.4K DKK
Volume
11
Financial calendar
Interim report
20.08.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
LSP V Coöperatieve U.A. | 7.8 % | 7.8 % |
Sunstone Life Science Ventures Fund II K/S | 5.2 % | 5.2 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Indkaldelse Til Ordinær Generalforsamling Den 18. April 2024 Kl. 15:00
Årsregnskab 2023 – Et begivenhedsrigt år for selskabet
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools